|
1) 秋葉 隆. 本邦の血液透析施設におけるC型ウイルス肝炎感染の実態調査. 日透医誌. 2004; 19: 30-2
|
|
|
|
|
2) Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004; 65: 2335-42
|
|
|
|
|
3) 日本透析医学会, 編. 図説 わが国の慢性透析療法の現況 2007年12月31日現在. 東京: 日本透析医学会; 2008
|
|
|
|
|
|
4) Iwasa Y, Otsubo S, Sugi O, et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol. 2008; 12: 53-7
|
|
|
|
|
|
5) 菊地 勘, 秋葉 隆, 新田孝作. 慢性血液透析患者におけるC型肝炎ウイルス感染のサーベイランス. 東女医大誌. 2006; 76: 32-7
|
|
|
|
|
|
6) de Paula Farah K, Carmo RA, de Figueiredo Antunes CM, et al. Hepatitis C, HCV genotypes and hepatic siderosis in patients with chronic renal failure on haemodialysis in Brazil. Nephrol Dial Transplant. 2007; 22: 2027-31
|
|
|
|
|
|
7) 菊地 勘, 新田孝作, 秋葉 隆. 透析患者の感染症対策 血液透析中のC型慢性肝炎患者に対するインターフェロン(IFN)治療. 日本透析医学会雑誌. 2007; 40 Suppl 1: 326
|
|
|
|
|
|
8) Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000; 11: 1896-902
|
|
|
|
|
|
9) Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int. 1998; 53: 1374-81
|
|
|
|
|
|
10) Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant. 2001; 16: 1669-74
|
|
|
|
|
|
11) Mahmoud IM, Sobh MA, El-Habashi AF, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract. 2005; 100: 133-9
|
|
|
|
|
|
12) Fabrizi F, Martin P, Dixit V, et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant. 2005; 5: 2433-40
|
|
|
|
|
|
13) Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999; 29: 257-63
|
|
|
|
|
|
14) Fabrizi F, Dixit V, Messa P, et al. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2008; 15: 79-88
|
|
|
|
|
|
15) Gordon CE, Uhlig K, Lau J, et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008; 51: 263-77
|
|
|
|
|
|
16) Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006; 21: 575-80
|
|
|
|
|
|
17) Sporea I, Popescu A, Sirli R, et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol. 2006; 12: 4191-4
|
|
|
|
|
|
18) Rendina M, Schena A, Castellaneta NM, et al The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007; 46: 768-74
|
|
|
|
|
|
19) Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006; 13: 316-21
|
|
|
|
|
|
20) Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut. 2008; 57: 525-30
|
|
|
|
|
|
21) 菊地 勘, 秋葉 隆. 透析患者のC型肝炎とインターフェロン治療. 臨床透析. 2007; 23(4): 479-48
|
|
|
|